After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Ionis Pharmaceuticals Inc. (IONS) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $39.25. The Ionis Pharmaceuticals Inc. has recorded 232,453 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies.
IONS belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $39.25 and fluctuated between $39.38 as its day high and $37.33 as its day low. The current market capitalization of Ionis Pharmaceuticals Inc. is $5.51B. A total of 1.11 million shares were traded on the day, compared to an average of 1.03M shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, IONS has seen 2 BUY and 1 SELL insider trades, representing the acquisition of 2,193 and the disposition of 144 shares. Over the last 12 months, there were 43 BUYs and 19 SELLs from insiders. Insiders purchased 293,006 shares during that period but sold 81,595.
In the most recent transaction, Swayze Eric sold 460 shares of IONS for 44.55 per share on Sep 08. After the transaction, the EVP Research now owns 19,892 company shares. In a previous transaction on Jul 15, KLEIN JOSEPH III sold 1,333 shares at 38.24 per share. IONS shares that Director owns now total 18,791.
Among the insiders who sold shares, Swayze Eric disposed of 378 shares on Apr 21 at a per-share price of $44.15. This resulted in the EVP Research holding 20,353 shares of IONS after the transaction. In another insider transaction, O’NEIL PATRICK R. sold 6,792 shares at $40.06 per share on Apr 12. Company shares held by the EVP CLO & General Counsel now total 34,536.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for IONS in the last 3 months, the mean price target is $50.10 with high estimates of $92.00 and low estimates of $24.00. In terms of 52-week highs and lows, IONS has a high of $48.82 and a low of $28.25.
As of this writing, IONS has an earnings estimate of -$0.74 per share for the current quarter. EPS was calculated based on a consensus of 16 estimates, with a high estimate of -$0.51 per share and a lower estimate of -$0.94. The company reported an EPS of -$0.46 in the last quarter, which was 35.20% higher than expectations of -$0.71.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 22 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IONS is Sell with a score of 3.54. A total of 10 analysts rated the stock as Buy while 1 rated it as Overweight while 6 rated it as Hold. Among the other participants, 2 thought the stock was Underweight and 3 thought it should be Sold.